Raymond James & Associates Blueprint Medicines Corp Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Raymond James & Associates holds 13,550 shares of BPMC stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,550
Previous 9,335
45.15%
Holding current value
$1.25 Million
Previous $885,000
64.97%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding BPMC
# of Institutions
340Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$614 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$604 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.87MShares$543 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$299 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$227 Million8.22% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.52B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...